Biocon has recently informed exchanges that its Bengaluru API facility (Site 1) has received a Voluntary Action Indicated (VAI) status from the U.S. Food and Drug Administration (US FDA). This follows a surveillance inspection conducted from Septembe
Aman Shukla is a journalist who specializes in technology, entertainment, and consumer products. With a focus on providing readers with the latest deals and discounts, Aman's articles aim to inform and help readers make informed purchasing decisions. His work has been featured in Business Upturn and he currently writes for India Shorts.